Alliance Wealth Advisors LLC UT Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Alliance Wealth Advisors LLC UT reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,019 shares of the biopharmaceutical company’s stock after selling 138 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Gilead Sciences were worth $2,680,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in Gilead Sciences during the 3rd quarter valued at $25,000. HHM Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the last quarter. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Finally, Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 598,414 shares of company stock worth $55,953,200. Company insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Monday. Bank of America restated a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $98.38 on Tuesday. The firm has a market cap of $122.61 billion, a P/E ratio of 1,093.11, a PEG ratio of 1.37 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $99.45. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50 day moving average of $92.42 and a 200 day moving average of $85.96.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. As a group, research analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.